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ABSTRACT
Objective: The current study was carried out to investigate the xanthine oxidase inhibitory, antihyperuricemic, anti-inflammatory, and antinociception 
activity of α-lipoic acid (LA) in gouty model of rats.
Methods: Enzyme assay was done using bovine milk xanthine oxidase (XO). The XO inhibitory activity in vitro was performed using different doses 
of α-LA, and the degree of XO inhibition was expressed as IC50. The antihyperuricemic activity of α-LA was tested in the potassium oxonate-induced 
hyperuricemic rats for 7 consecutive days of oral treatment of 10, 25, and 50 mg/kg doses. The anti-inflammatory activity was achieved through 
monosodium urate crystal-induced inflammation hind paw model in mice. The antinociception effects of α-LA were explored using both of writhings 
induced by acetic acid test and hot plate test.
Results: The study results revealed that the α-LA has a potent activity of XO inhibition with IC50 = 2.93 µg/mL. Furthermore, these results showed 
that all doses of α-LA were able to significant reduce of each the following: Serum uric acid levels in the hyperuricemic rats, hind paw thickness of 
mice at all periods of time assessment, and writhings number in the acetic acid-induced writhing test, while, the same doses significantly increased 
the reaction latency in mice at hot plate test.
Conclusion: The α-LA showed a significant effect on the evaluated models, and therefore it may be a promising agent for the treatment of gout since 
it possesses XO inhibitory, antihyperuricemic, anti-inflammatory, and antinociception activity.
Keyword: α-lipoic acid, Xanthine oxidase inhibitor, Antihyperuricemic, Anti-inflammatory, Antinociceptive, Gout.
INTRODUCTION
Uric acid (UA) is the ultimate product of nucleic acids degradation in 
most mammals consequently to the action of xanthine oxidase (XO) 
enzyme [1]. The two-thirds of UA pool comes from the breakdown of 
endogenous purines while the remaining quantity resulted from dietary 
(exogenous) purines. Human is the only organism from the rest of the 
mammals cannot convert UA to a more soluble compound, allantoin 
due to lack of the uricase enzyme [2]. Most of UA released from the 
human body by the renal tract while the gastrointestinal tract secretes 
the residual. Approximately 90% of the UA that secreted by the kidneys 
is reabsorbed by renal tubules into the blood. The absence of uricase 
enzyme association with massive reabsorption of filtered UA results in 
an elevation of UA levels in the human blood that is frequently ten-folds 
those of most other mammals [3]. As a result, high serum UA may be 
one of the main serious factors for developing of the hyperuricemia, 
which may lead to the occurrence of gout [4,5]. Hyperuricemia can 
be expressed as the blood UA level larger than the normal values 
in both females (6 mg/dL) and males (7 mg/dL), and it arises from 
underexcretion and/or overproduction of UA, where the main cause of 
hyperuricemia in the gouty patients is urate underexcretion [6,7]. Gouty 
arthritis is an inflammatory, metabolic defect affecting elderly men 
and postmenopausal women that originates due to the formation and 
accumulation of monosodium urate (MSU) crystals in the kidneys and 
inflamed joints [7]. Clinical signs of such inflammatory disorder include 
gouty flares that represented by quite pain, edema, warmness, and 
redness [8]. Persisting of hyperuricemia leads to further MSU deposits 
crystals inducing chronic inflammatory responses that may lead to 
the tophi formation, chronic joint destruction, renal insufficiency, and 
cardiovascular problems [9,10]. Therapeutic management of gout 
involves two methods of treatment: The first one is rapid and aims to 
cure the nociception and inflammation caused by acute inflammatory 
attacks of gout, while the second method involves the reducing the levels 
of UA in the blood into normal values in a long-term manner [5,11]. 
The first approach to treatment comprises many types of drugs such 
as nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, and 
corticosteroids; however, prolonged use of these drugs may produce 
critical side effects such as ulcerations and toxicity of gastrointestinal 
tract and renal toxicity [1]. The second approach of gout treatment, 
urate-lowering drugs (ULD) includes two categories of drugs: (a) XO 
inhibitors such as allopurinol and febuxostat and (b) uricosurics agents 
such as probenecid and benzbromarone. In general, XO inhibitors are 
indicate to urate-overproduction patients, whereas uricosurics drugs 
are prescribe to urate-underexcretion patients. Although the use of 
ULD medication is effective in gout cure, but not without adverse effects 
such as severe hypersensitivity reactions, hepatotoxicity and renal 
defects [12]. Until now, although severity and serious complications 
of gout, there are still a few drugs that are used in the treatment, in 
addition to the serious side effects for many of these drugs. Therefore, 
it necessary to search for new effective and safe urate-lowering agents 
with analgesic, antioxidant, and anti-inflammatory activities [13,14].
Alpha-lipoic acid (α-[LA]; also named as thioctic acid) is a dithiol 
substance existing in animals and plants that function as a coenzyme 
for the several enzymes of the energy-producing metabolism in the 
mitochondria [15,16]. α-LA acts as a potent antioxidant in the all parts 
of cellular environments due to its good solubility in both water and 
lipid [17]. In the different tissues of the human body, α-LA is rapidly 
changed into the reduced status, dihydrolipoic acid (DHLA) that 
works as more active than α-LA itself [18,19]. As well as the valuable 
antioxidant activity, α-LA and DHLA possess many different biological 
activities like the regeneration ability of other antioxidants (Vitamin E 
and C and glutathione) from oxidized forms into active reduced states, 
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also these acids are effective chelators of toxic metals and male 
fertility enhancers. Many studies revealed the ability of α-LA in the 
treatment and prevention of different oxidative-mediated pathological 
defects such as inflammation, diabetes neuropathy, cells aging, and 
cardiovascular diseases [20-22]. According to the potent antioxidant 
activity of α-LA, this study aimed to investigate the antinociception, 
anti-inflammatory and antihyperuricemic activity of α-LA in the gouty 
arthritis model in the rats.
MATERIALS AND METHODS
Animals
This study included the use of two types of animals and male in gender: 
Wistar rats (150–170 g) and albino Swiss mice. (25–30 g) which 
were supplied from the unit of animals’ house at College of Pharmacy, 
Basrah University. Both rats and mice were separated into different 
groups (n=6), then the animals were accommodated in isolated plastic 
cages and kept in the animal’s room under a regulated condition at 
temperature 25±2°C and humidity 30±15% with the 12-h dark/12-h 
light cycle for a week before being used for acclimatization. They were 
fed standard chow and water ad libitum, and all of dealing procedures 
with animals that described in this study were authorized by Animal 
Ethics Committee, University of Basrah, Iraq (No. 2013/32).
In vitro XO inhibitory activity
The XO inhibitory effect of α-LA was assessed spectrophotometrically 
at 290 nm according to Sunarni et al. [23] and Yumita et al. [24] with 
minor changes. The mixture assay consists of 0.9 mL of 0.05 M sodium 
phosphate buffer (pH 7.5 at 25°C), 1 mL of α-LA solution (100 µg/mL 
in DMSO), and 0.1 mL of XO enzyme solution (0.1 unit/mL in phosphate 
buffer, pH 7.5) was prepared in cold buffer directly before using. After 
a 15-min preincubation at 25°C, the reaction was started by addition of 
2000 µL of a freshly prepared solution of substrate (0.15 mm xanthine 
solution). Next, a further incubation process was achieved for the 
reaction mixture at 25°C for 30 min. After addition of 1 mL of 1N HCl 
solution into assay mixture for stopping the reaction, the absorbance 
was recorded at wavelength 290 nm using UV/Vis spectrophotometer 
against the blank which is prepared in the same procedure but with 
the replacement of enzyme solution by phosphate buffer. The positive 
control solution was prepared using allopurinol (100 µg/mL) in 
DMSO. The inhibitory activity of XO was established as the inhibition 
percentage (%):
% XO inhibition = (1-α/β) × 100
Where α is the activity of XO without tested substance (α-LA) and β is 
the activity of XO with the presence of α-LA.
Different concentrations of both α-LA and allopurinol (100, 50, 25, 
10, 5, 4, 3, 2, and 1 µg/mL) were used for evaluation of XO inhibitory 
activities; then, the dose-response logarithmic curve was applied to 
determine the median maximum inhibitory concentration IC50.
Drug administration
Allopurinol and α-LA were suspended in 0.5% sodium salt of 
carboxymethyl cellulose, Na (vehicle). Potassium oxonate (250 mg/kg), 
indomethacin (3 mg/kg), and MSU crystals (40 mg/mL) were suspended 
in 0.9% sterile saline. All solutions were prepared freshly before use for 
in vivo experiments.
Evaluation of antihyperuricemic activity
The antihyperuricemic activity of α-LA investigated using the potassium 
oxonate-induced hyperuricemia in the rat’s model according to Haidari 
et al. [25] and Nguyen et al. [26] with modifications. Animals were fasted 
by withdrawing of food and water 2 h before drugs administration. 
Experimental animals (rats) were divided randomly into six groups 
(n=6). The uricase inhibitor (potassium oxonate) at a dose of 250 mg/kg 
was injected intraperitoneally (i.p.) to rats of groups (2–6) in the 1st, 3rd, 
and 7th days of the experiment period. Rats groups were administered 
with oral treatments of the vehicle, allopurinol, and α-LA solutions by 
oral gavage 1 h after the administration of potassium oxonate, once a 
day for 7 consecutive days of the experiment. Animals of normal control 
(Group 1) and hyperuricemic control (Group 2) were received the only 
vehicle through oral administration. Standard drug group (Group 3) 
was treated orally with allopurinol (10 mg/kg). Sample Groups 4–6 
were treated orally with α-LA at the doses 10, 25, and 50 mg/kg, 
respectively, once a day, throughout the days of the experiment. Whole 
blood samples were collected from each rat by cutting tail vein 2 h after 
last administration of tested drugs. The blood was permitted to clot for 
0.5 h at room temperature and then centrifuged at 3500 rpm for 5 min 
to get the serum. The sera were stored at −20°C until the UA is assayed.
UA assay
The enzymatic-colorimetric method employed to determine the serum 
UA levels using a standard diagnostic kit (BioLab., France).
Anti-inflammatory effect of α-LA on gouty arthritis inflammation 
model in mice
An experimental model of gout as previously mentioned by Lima et al. [27] 
and Ferrari et al. [28] with some modifications carried out to investigate 
the anti-inflammatory effect of α-LA. The assay was performed within a 
period of 3 days. Animals (mice) were distributed into six groups (n=6). 
On the 1st day of the study, the inflammatory induction was achieved by 
intradermal injection of 100 µL (4 mg) of MSU crystals suspension into 
the right hind paws of mice. All groups of animals (2–6) were injected 
with MSU, except for normal control group (Group 1), which were 
injected with 100 µL of 0.9% sterile saline solution. All treatments were 
administered by oral gavage an hour before injection of MSU suspension 
on the 1st day of the experiment and repeated a once daily at the same 
time, for another 2 days. Mice of Group 1 and Group 2 were treated with 
the vehicle and served as normal control group and MUS-induced gouty 
(negative) control group, respectively. Group 3 animals were treated 
with a standard nonsteroidal anti-inflammatory agent, indomethacin 
(3 mg/kg) and served as a positive control group. Mice of groups (4–6) 
were treated with α-LA at the doses 10, 25, and 50 mg/kg. Thickness 
of mouse hind paw was measured with digital Vernier caliper (Numit, 
China) at 0, 4, 24, and 48 h after MUS injection and the inflammatory 
edema were expressed as a percentage of thickness variation (Δ).
Evaluation of analgesic activity of α-LA
Writhing test
This test performed as formerly explained by Spindola et al. [29] with 
modifications. Male albino mice were distributed into five groups each 
containing five mice. Animals were fasted for overnight and then were 
treated as following: Group 1 of mice were treated (10 mL/kg) of vehicle 
(0.9% saline solution) and served as negative control group and Group 2 
of mice were treated 10 mg/kg of indomethacin and served as positive 
control group, while mice groups (3–5) were received 10, 25, and 
50 mg/kg of α-LA, respectively. All treatments of vehicle, indomethacin, 
and α-linoleic acid were given orally by gastric gavage. After of 1 h, mice 
in all groups were treated with 10 mL/kg of 1% v/v acetic acid solution 
intraperitoneally (i.p) to induce the nociception state (pain). 5 min 
after the giving of acetic acid, the number of observed writhings in 
each mouse was counted for 15 min. The percentage inhibition (I%) of 
writhing (abdominal constrictions) was used to evaluate the analgesia 
potency and was calculated as the following formula:
Inhibition % (I%) = (Nc−Nt/Nc) × 100
Where Nc is the average of writhing numbers in the negative control 
group and Nt is the average of writhing numbers in the treated groups.
Hot plate test in mice
One of the evaluation methods of antinociception activity is the hot 
plate test in mice, which performed according to the previously 
described in the method of Schmidt et al. [30] with modifications. Five 
groups of Swiss albino mice of both sexes were used with six animals in 
each group in this experiment. Mice were fasted for overnight and then 
were treated as following: Group 1 of mice were treated (10 mL/kg, p.o) 
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of vehicle (0.9% saline solution) and served as negative control group 
and Group 2 of mice were intraperitoneally treated 10 mg/kg of 
tramadol and served as positive control group, while mice groups (3–
5) were orally received 10, 25, and 50 mg/kg of α-LA, respectively. 1 h 
of all treatments, mice were putted inside glass cylinder placed on the 
well-regulated hot plate maintained 55±1°C, and the difference time 
between placing of mice on the surface of hot plate and the occurrence 
of fore hind paws licking or jumping was recorded as reaction time. 
It has been taken into consideration that the cutoff period should not 
exceed 20 s maximum latency to avoid the injury of paws.
Statistical analysis
The results of all trials in this study stated as mean±structural equation 
modeling. Statistical analysis carried out by (ANOVA) pursued by the 
Dennett’s t-test. The values of probability (P) <0.05 are considered as 
statistically significant.
RESULTS AND DISCUSSION
In vitro XO inhibitory activity
The inhibitory effects of α-LA and allopurinol for bovine milk XO at 
different concentrations represented in Table 1. Each has revealed 
>50% of XO inhibition at the concentration 4 µg/mL. At highest 
concentration 100 µg/mL, the α-LA resulted in 88% of XO inhibition 
activity, whereas the standard XO inhibitor, allopurinol demonstrated 
95% of XO inhibition activity at the same concentration. The XO 
inhibitory effects for both α-LA and allopurinol were also stated in the 
term of IC50, which is represent the concentration of standard drug 
or tested sample that is required for 50% inhibition of XO enzyme 
activity under the same experimental conditions. The IC50 values were 
calculated according to the dose-response logarithmic curve using 
GraphPad Prism V 6.05 program (GraphPad Prism software, Inc., 
USA), where the value was equal to 1.734 µg/mL for allopurinol and 
2.930 µg/mL for α-LA, respectively, as shown in Fig. 1.
Antihyperuricemic activity
To assess the existence of antihyperuricemic effect of the α-LA, the 
potassium oxonate-induced hyperuricemia model in rats used in this 
study. As shown in Table 2, the intraperitoneal injection of uricase 
inhibitor, potassium oxonate (250 mg/kg) obviously increased 
the serum UA levels in rats compared with healthy normal control 
group. The administration of standard XO inhibitor, allopurinol 
(10 mg/kg, p.o), was able to significantly reduce (p<0.001) the serum 
UA levels of hyperuricemic rats (positive control group) to values 
close of normal control. The consecutive 7-day treatment of rats with 
α-LA at the dose 10, 25, and 50 mg/kg significantly reduce (p<0.001) 
the serum UA levels as compared with hyperuricemic control group 
in all doses above.
Effect of α-LA on MSU crystal-induced inflammation in mice
As shown in Table 3, the injection of MSU crystals significantly 
increased (p<0.001) the thickness of the mice paws when compared 
to the normal animal group. The injection of both standard NSAIDs, 
indomethacin (3 mg/kg), and α-LA at all gradual doses (10, 25, and 
50 mg/kg) was able to achieve a significant reduction (p<0.001) in the 
paw thickness at all periods of time assessment.
Evaluation of analgesic activity of α-LA
Writhing test
The results presented in Table 4 revealed that standard drug, 
indomethacin (10 mg/kg) significantly reduced the number of acetic 
acid-induced writhings in mice (75%) compared to the negative control 
group (p<0.001). Similar to indomethacin, α-LA at 10 and 25 mg/kg 
was able to produce a significant antinociception effect (p<0.001) by 
reducing the number of writhings in mice (52% and 67%, respectively), 
while at 50 mg/kg, the α-LA showed higher capacity than indomethacin 
(79%) in reduction of the writhings number in mice induced by 
injection of acetic acid.
Hotplate test
The mean reaction time of pain responses to the thermal stimuli in 
the hot plate test is shown in Table 5. Three doses of α-LA (10, 25, and 
50 mg/kg, p.o.) significantly increased (p<0.001) the reaction times to 
the heat-induced pain in mice compared to the negative control group 
(vehicle). Positive drug, tramadol (10 m g/kg, s.c.) markedly increased 
(p<0.001) the mean of reaction times from 3.14 s at negative control 
group to 11.65 s.
DISCUSSION
Gout is a chronic inflammatory condition associated with the deposition 
of sodium urate crystals, resulting in severe pain and swollen joints and 
soft tissue. Treatment methods for gout management include the first 
treatment of acute gout attacks involving the use of anti-inflammatory 
and analgesic agents such as NSAIDs, colchicine, and corticosteroids. 
Subsequently, the lowering urate drugs such as allopurinol, febuxostat, 
and probenecid are used to treat hyperuricemia. Until now, the 
use of these drugs involves the emergence of many side effects, 
and none of the clinically available drugs can be used to treat the 
Table 1: XO inhibitory activity of α-LA and allopurinol at 
different concentrations












SEM: Standard error of the mean, LA: Lipoic acid, XO: Xanthine oxidase
Table 2: Effects of allopurinol and α-LA on the serum UA levels 
in the normal and potassium oxonate-induced hyperuricemic 
rats
Group Dose (mg/kg) n Serum UA (mg/dL)
Normal control − 6 1.2±0.2
Hyperuricemic control − 6 4.4±0.7










Each value is the mean±SEM, *p<0.05, **p<0.01, ***p<0.001 compared with 
hyperuricemic control. Data analyzed by using one-way ANOVA followed by 
Dennett’s test, SEM: Standard error of the mean, LA: Lipoic acid, UA: Uric acid
Fig. 1: Xanthine oxidase inhibitory activity and IC50 values of α-lipoic 
acid and allopurinol
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gout arthritis symptoms together such as pain, hyperuricemia, and 
inflammation [10]. The present study aimed to investigate the XO 
inhibitory, antihyperuricemic, anti-inflammatory, and antinociception 
activity of α-LA.
UA produced as a main final product of purine metabolism by the action 
of XO enzyme that accelerates the hypoxanthine conversion to xanthine 
and then xanthine into UA. Therefore, the inhibition of XO activity can 
be considered as a useful therapeutic method in the treatment of gout 
and other XO-related complications [25]. Different concentrations 
of α-LA and allopurinol were assessed for in vitro bovine milk XO 
inhibitory activity. The XO inhibition percentage results are revealed in 
Table 1 indicated that at the final concentration 100 µg/mL, the α-LA 
potentially inhibited the XO activity with 88% as compared to 95% for 
the standard drug, allopurinol at the same concentration. Further, the 
IC50 value for the α-LA (2.93 µg/mL) clearly denotes that it is a potent 
XO inhibitor as compared with the value of well-known XO inhibitor, 
allopurinol (IC50=1.73 µg/mL).
Potassium oxonate is a well-known uricase inhibitor in animal models of 
hyperuricemia due to low-cost and rapid-acting substance. The potassium 
oxonate-induced hyperuricemic rats are the most suitable animal model 
to assess new drugs that affect levels of UA in the blood [31]. In this study, 
treatment of rats with potassium oxonate resulted in a significant elevation 
in the serum urate levels as compared to normal group, revealing that the 
rat model has been successfully established. A 7-day oral treatment of the 
α-LA at doses (10, 25, and 50 mg/kg) significantly decreased (p<0.001) 
in a dose-dependent mode the serum UA levels when associated with 
the hyperuricemic control group. In contrast, the same treatment with 
the standard hypouricemic drug, allopurinol (10 mg/kg) also led to a 
significant reduction (p<0.001) in serum urate levels. The reduction in 
the serum UA levels and proceeded by a significant efficacy of inhibition 
of XO, these results designate that the overall activity of the α-LA as 
antihyperuricemic is markedly associated with inhibition of XO activity, 
and this may be the mechanism of action.
In this study, MSU crystal-induced inflammation model used to trigger 
the occurrence of gout acute attacks through the accumulation of 
the urate crystals in the joints, promoting the initiation of a series of 
inflammatory reactions, which, in turn, result in acute inflammation and 
tissue damage [32]. Injection of the MSU crystals produced an important 
increase in the thickness of mice hind paws as matched to the negative 
control. Treatment with both indomethacin at a dose (3 mg/kg) and 
α- LA at doses (10, 25, and 50 mg/kg) resulted in significant reduction 
in the thickness of mice paws at 4, 24, and 48 h of injection of MSU 
crystals. These results confirm the ability of α-LA to block the synthesis 
and releasing of inflammatory mediators because the α-LA can work 
efficiently in the initial and last stages of the inflammatory process.
The antinociception activity of new drugs can verify by assessing their 
effects centrally or peripherally, where the hot plate test used to evaluate 
the central acting analgesic effect and the acetic acid-induced writhings 
test used to evaluate the peripheral acting analgesic effect [33]. In 
the present study, we employed both techniques to not only verify 
antinociceptive influence but also to determine the mechanism action 
of the antinociceptive effect of α-LA. The inhibition of the acetic acid-
induced writhings is an indication of potential analgesic of α-LA. The 
pain induction by acetic acid is due to liberating endogenous substances 
such as histamine, serotonin, prostaglandins, and bradykinins and those 
which stimulate nerve endings [29]. Thus, the antinociceptive effect 
of α-LA may be peripherally mediated by the inhibition of synthesis 
and liberating of prostaglandins through inhibition of cyclooxygenase 
enzymes. Since acetic acid-induced contractions test involves several 
different types of nociceptive mechanisms, we have tested the hot 
plate to assess the possibility of α-LA from showing any central 
analgesic effect. The ability of α-LA to lengthen the reaction latency to 
the thermal-induced pain of mice by the hot plate strongly supports 
its most central analgesic activity. Consequently, α-LA may exhibit its 
antinociceptive effect by involving peripheral and central mechanisms.
CONCLUSIONS
The results of the current study demonstrated that the α-LA has 
remarkable effects in the treatment of gout and associated diseases. It 
was noted that it was able to potentially reduce the urate levels in the 
Table 3: Effect of α-LA on MSU crystals-induced inflammation hind paw in mice
Group Dose (mg/kg) Thickness variation Δ (mm) in paw edema
4h 24 h 48 h
Normal control − 0.2±0.11 0.17±0.07 0.08±0.06
Negative control − 1.81±0.25 1.52±0.19 1.05±0.13













Each value is the mean±SEM for six mice, *p<0.05, **p<0.01, ***p<0.001 compared with normal control. Data analyzed by using one-way ANOVA followed by Dennett’s 
test, SEM: Standard error of the mean, LA: Lipoic acid, MSU: Monosodium urate
Table 4: Antinociceptive effect of α-LA on the acetic acid-induced writhings in mice
Group Dose (mg/kg) Number of writhings Inhibition (%)
Negative control (vehicle) − 46.31±3.24 −
Positive control (indomethacin) 10 11.22±1.62*** 75.77







Each value is the mean±SEM, *p<0.05, **p<0.01, ***p<0.001 compared with negative control. Data analyzed by using one-way ANOVA followed by Dennett’s test, 
SEM: Standard error of the mean, LA: Lipoic acid
Table 5: Antinociceptive effect of α-LA by hot plate method in 
mice
Group Dose (mg/kg) Reaction 
time (seconds)
Negative control (vehicle) − 3.14±0.57






Each value is the mean±SEM, *p<0.05, **p<0.01, ***p<0.001 compared with 
negative control. Data analyzed by using one-way ANOVA followed by Dennett’s 
test, SEM: Standard error of the mean, LA: Lipoic acid
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serum of potassium oxonate-induced hyperuricemic rats through the 
potent inhibitory activity for XO in vitro. Furthermore, α-LA was able 
to reduce MSU crystal-induced edema hind paw in mice significantly. 
Furthermore, α-LA possesses significant efficient as peripheral and 
central analgesic agent through acetic acid-induced writhing and hot 
plate tests.
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